Nuformix has received an FDA request for clarification on its Orphan Drug Designation application for tranilast under the NXP002 programme. The company also reported its Open Offer was oversubscribed by 408%, raising around £228,000 before expenses...
Nuformix will attend the European Respiratory Society Congress in Amsterdam from 28 September 2025, where it will present new findings from its lead programme, NXP002, an inhaled treatment for idiopathic pulmonary fibrosis...
Nuformix has submitted an application to the US FDA for Orphan Drug Designation for tranilast, the active ingredient in its NXP002 inhaled therapy for idiopathic pulmonary fibrosis...
Nuformix plc will showcase groundbreaking results on NXP002 at the American Thoracic Society Congress in San Francisco, addressing fibrosis and oncology challenges...
Nuformix Plc's Dr. Dan Gooding discusses the EMA's positive orphan drug designation for NXP002, highlighting its significance in treating idiopathic pulmonary fibrosis...
Nuformix plc (LON:NFX) reports promising developments in its drug NXP002 for treating fibrotic lung diseases, highlighting significant operational and financial insights...
Executive Director Dr Dan Gooding outlines how this validation not only highlights the urgent unmet need in IPF but also sharpens Nuformix’s commercial edge with 10 years of market exclusivity and accelerated development support..
Nuformix plc (LON:NFX) has received a positive opinion from the EMA for Orphan Drug Designation of NXP002 in treating Idiopathic Pulmonary Fibrosis (IPF)...
Nuformix plc (LON:NFX) has, effective immediately, relocated its registered office to a new London address and appointed Shaun Zulafqar as Company Secretary...
Nuformix plc announces promising re-analysis results for NXP002, targeting unmet needs in fibrosis and oncology, offering insights into new treatment pathways...
Nuformix plc (LON:NFX) raises £168,750 for fibrosis drug development through a new share placing, advancing its NXP002 programme and corporate goals...
Nuformix plc (LON:NFX) targets unmet needs in fibrosis and oncology via drug repurposing, focusing on partnering its NXP002 lead program for IPF and PPF...
Nuformix plc (LON:NFX) Executive Director Dr. Dan Gooding reveals insights on new patents for NXP002 & NXP004, interim results, and future plans in an exclusive interview...
Nuformix Plc provides a patent update for its NXP002 and NXP004 programs in fibrosis and oncology. Learn more in this interview with Executive Director Dr. Dan Gooding...
Nuformix has received an FDA request for clarification on its Orphan Drug Designation application for tranilast under the NXP002 programme. The company also reported its Open Offer was oversubscribed by 408%, raising around £228,000 before expenses...
Nuformix will attend the European Respiratory Society Congress in Amsterdam from 28 September 2025, where it will present new findings from its lead programme, NXP002, an inhaled treatment for idiopathic pulmonary fibrosis...
Nuformix has submitted an application to the US FDA for Orphan Drug Designation for tranilast, the active ingredient in its NXP002 inhaled therapy for idiopathic pulmonary fibrosis...
Nuformix plc will showcase groundbreaking results on NXP002 at the American Thoracic Society Congress in San Francisco, addressing fibrosis and oncology challenges...
Nuformix Plc's Dr. Dan Gooding discusses the EMA's positive orphan drug designation for NXP002, highlighting its significance in treating idiopathic pulmonary fibrosis...
Nuformix plc (LON:NFX) reports promising developments in its drug NXP002 for treating fibrotic lung diseases, highlighting significant operational and financial insights...
Executive Director Dr Dan Gooding outlines how this validation not only highlights the urgent unmet need in IPF but also sharpens Nuformix’s commercial edge with 10 years of market exclusivity and accelerated development support..
Nuformix plc (LON:NFX) has received a positive opinion from the EMA for Orphan Drug Designation of NXP002 in treating Idiopathic Pulmonary Fibrosis (IPF)...
Nuformix plc (LON:NFX) has, effective immediately, relocated its registered office to a new London address and appointed Shaun Zulafqar as Company Secretary...
Nuformix plc announces promising re-analysis results for NXP002, targeting unmet needs in fibrosis and oncology, offering insights into new treatment pathways...
Nuformix plc (LON:NFX) raises £168,750 for fibrosis drug development through a new share placing, advancing its NXP002 programme and corporate goals...
Nuformix plc (LON:NFX) targets unmet needs in fibrosis and oncology via drug repurposing, focusing on partnering its NXP002 lead program for IPF and PPF...
Nuformix plc (LON:NFX) Executive Director Dr. Dan Gooding reveals insights on new patents for NXP002 & NXP004, interim results, and future plans in an exclusive interview...
Nuformix Plc provides a patent update for its NXP002 and NXP004 programs in fibrosis and oncology. Learn more in this interview with Executive Director Dr. Dan Gooding...
